| Original language | English (US) |
|---|---|
| Pages (from-to) | 1985-1987 |
| Number of pages | 3 |
| Journal | JACC: Cardiovascular Interventions |
| Volume | 12 |
| Issue number | 19 |
| DOIs | |
| State | Published - Oct 14 2019 |
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
The Value of Left Ventricular Support in Patients With Reduced Left Ventricular Function Undergoing Extensive Revascularization : An Analysis From the PROTECT-II Randomized Trial. / Burke, David A.; Kundi, Harun; Almonacid, Alexandra et al.
In: JACC: Cardiovascular Interventions, Vol. 12, No. 19, 14.10.2019, p. 1985-1987.Research output: Contribution to journal › Letter › peer-review
}
TY - JOUR
T1 - The Value of Left Ventricular Support in Patients With Reduced Left Ventricular Function Undergoing Extensive Revascularization
T2 - An Analysis From the PROTECT-II Randomized Trial
AU - Burke, David A.
AU - Kundi, Harun
AU - Almonacid, Alexandra
AU - O'Neill, William
AU - Moses, Jeffrey
AU - Kleiman, Neal
AU - Dixon, Simon
AU - Palacios, Igor
AU - Guzman, Luis A.
AU - Ohman, E. Magnus
AU - Popma, Jeffrey J.
AU - Pinto, Duane S.
N1 - Funding Information: Please note: Dr. O'Neill has been a consultant for Abiomed, Edwards Lifesciences, Boston Scientific, and Abbott. Dr. Ohman has been a consultant for 3D Communications, Abiomed, ACI Clinical, Biotie, Cara Therapeutics, Cardinal Health, Faculty Connection, Imbria, Impulse Medical, Janssen Pharmaceuticals, Medscape, Milestone Pharmaceuticals, and Xylocor; and has received research grants from Abiomed, Chiesi, and Portola. Dr. Popma has served on a medical advisory board for Boston Scientific; and has received institutional grants from Boston Scientific; Medtronic, Abiomed, and Abbott. Dr. Pinto is a consultant for Abbott Vascular, Abiomed, Teleflex, NuPulse, Medtronic, and Opsens; has received institutional grants from Boston Scientific, and received stock options from NuPulse. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. Funding Information: Please note: Dr. O'Neill has been a consultant for Abiomed, Edwards Lifesciences, Boston Scientific, and Abbott. Dr. Ohman has been a consultant for 3D Communications, Abiomed, ACI Clinical, Biotie, Cara Therapeutics, Cardinal Health, Faculty Connection, Imbria, Impulse Medical, Janssen Pharmaceuticals, Medscape, Milestone Pharmaceuticals, and Xylocor; and has received research grants from Abiomed, Chiesi, and Portola. Dr. Popma has served on a medical advisory board for Boston Scientific; and has received institutional grants from Boston Scientific; Medtronic, Abiomed, and Abbott. Dr. Pinto is a consultant for Abbott Vascular, Abiomed, Teleflex, NuPulse, Medtronic, and Opsens; has received institutional grants from Boston Scientific, and received stock options from NuPulse. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
PY - 2019/10/14
Y1 - 2019/10/14
UR - http://www.scopus.com/inward/record.url?scp=85072606114&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85072606114&partnerID=8YFLogxK
U2 - 10.1016/j.jcin.2019.07.050
DO - 10.1016/j.jcin.2019.07.050
M3 - Letter
C2 - 31601396
AN - SCOPUS:85072606114
VL - 12
SP - 1985
EP - 1987
JO - JACC: Cardiovascular Interventions
JF - JACC: Cardiovascular Interventions
SN - 1936-8798
IS - 19
ER -